Sarepta Therapeutics (SRPT) Rating Reiterated by HC Wainwright

Sarepta Therapeutics (NASDAQ:SRPT)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research report issued on Monday. They currently have a $96.00 target price on the biotechnology company’s stock. HC Wainwright’s price objective suggests a potential downside of 2.79% from the stock’s current price.

SRPT has been the topic of a number of other reports. Credit Suisse Group reiterated a “hold” rating and issued a $81.00 price objective on shares of Sarepta Therapeutics in a research report on Monday, March 12th. Leerink Swann lifted their price target on Sarepta Therapeutics from $88.00 to $121.00 and gave the company an “outperform” rating in a research report on Tuesday, May 15th. BidaskClub lowered Sarepta Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, March 29th. Goldman Sachs Group lifted their price target on Sarepta Therapeutics from $84.00 to $127.00 and gave the company a “buy” rating in a research report on Friday, May 18th. Finally, SunTrust Banks lifted their price target on Sarepta Therapeutics to $95.00 and gave the company a “buy” rating in a research report on Friday, March 16th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $92.18.

Shares of SRPT stock opened at $98.76 on Monday. The company has a market capitalization of $6.40 billion, a PE ratio of -60.22 and a beta of 1.35. Sarepta Therapeutics has a fifty-two week low of $31.23 and a fifty-two week high of $100.30. The company has a debt-to-equity ratio of 0.55, a quick ratio of 12.28 and a current ratio of 13.37.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Thursday, May 3rd. The biotechnology company reported ($0.55) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.32) by ($0.23). The business had revenue of $64.60 million during the quarter, compared to the consensus estimate of $65.31 million. Sarepta Therapeutics had a negative return on equity of 24.68% and a negative net margin of 83.88%. Sarepta Therapeutics’s quarterly revenue was up 295.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.57) earnings per share. research analysts forecast that Sarepta Therapeutics will post -1.92 earnings per share for the current year.

A number of large investors have recently made changes to their positions in SRPT. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Sarepta Therapeutics by 39.5% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,448 shares of the biotechnology company’s stock valued at $192,000 after buying an additional 977 shares during the last quarter. Prentiss Smith & Co. Inc. purchased a new position in Sarepta Therapeutics during the fourth quarter valued at $199,000. Arrowstreet Capital Limited Partnership purchased a new position in Sarepta Therapeutics during the fourth quarter valued at $217,000. Aperio Group LLC purchased a new position in Sarepta Therapeutics during the fourth quarter valued at $219,000. Finally, Bayesian Capital Management LP purchased a new position in Sarepta Therapeutics during the first quarter valued at $221,000. Institutional investors and hedge funds own 86.55% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin.

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yankees Former Ace Ron Guidry Says Luis Severino Will Break His Records
Yankees Former Ace Ron Guidry Says Luis Severino Will Break His Records
Ruptured Biceps Tendon Ends Miguel Cabrera’s Season
Ruptured Biceps Tendon Ends Miguel Cabrera’s Season
Dodgers Getting Big Unexpected Lift from Three Players
Dodgers Getting Big Unexpected Lift from Three Players
What does legal betting mean for the baseball industry?
What does legal betting mean for the baseball industry?
Dodgers Use Nine Pitchers in Nine-Inning Game
Dodgers Use Nine Pitchers in Nine-Inning Game
Max Scherzer Throws Second Career Immaculate Inning
Max Scherzer Throws Second Career Immaculate Inning


Leave a Reply

 
© 2006-2018 BBNS.